Table 2.
Summary of Institutional Flow Results on Blasts
| Diagnosis | CD13a | CD33a | CD34a | CD117a | CD38a | CD7a | CD41a | CD42ba | CD61a | CD36a | CD71a | CD56a |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDS | 28/34 (82) | 41/42 (98) | 28/42 (67) | 35/35 (100) | 12/12 (100) | 37/38 (97) | 21/27 (78) | 6/6 (100) | 26/34 (76) | 13/13 (100) | 6/6 (100) | 16/24 (67) |
| AML-MK | 37/41 (90) | 45/46 (98) | 36/43 (84) | 39/41 (95) | 13/13 (100) | 44/44 (100) | 31/36 (86) | 6/6 (100) | 33/40 (83) | X | 9/10 (90) | 19/22 (86) |
| AML-E | 8/9 (89) | 10/10 (100) | 5/8 (63) | 9/10 (90) | 5/5 (100) | 10/10 (100) | 0/5 (0) | X | 0/8 (0) | 5/5 (100) | 5/5 (100) | 3/5 (60) |
| AML-MK/E | 15/16 (94) | 18/18 (100) | 13/15 (87) | 14/14 (100) | 9/9 (100) | 20/20 (100) | 12/16 (75) | 3/3 (100) | 12/15 (80) | 15/15 (100) | 10/10 (100) | 7/8 (88) |
| AML-U | 9/10 (90) | 10/10 (100) | 5/10 (50) | 10/10 (100) | 6/6 (100) | 10/10 (100) | 0/6 (0) | 0/2 (0) | 0/7 (0) | X | X | 5/6 (83) |
| AML-NOS | 3/3 (100) | 3/3 (100) | 4/4 (100) | 3/3 (100) | X | 2/2 (100) | X | X | 0/1 (0) | X | X | X |
Abbreviations: AML, acute myeloid leukemia; AML-E, AML with erythroblastic differentiation; AML-MK, AML with megakaryoblastic differentiation; AML-MK/E, AML with mixed MK and E differentiation; AML-NOS, AML with insufficient information for sublineage classification; AML-U, AML with no identifiable sublineage differentiation; CD, cluster of differentiation; MDS, myelodysplastic syndrome; X, no cases tested.
a
Cases positive/cases tested (% positive of tested cases).